Skip to content

Menu

LexBlog, Inc. logo
CommunitySub-MenuPublishersChannelsProductsSub-MenuBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAboutContactResourcesSubscribeSupport
Join
Search
Close

To certify or not to certify? FDA has answered the question

By Robert Church, Heidi Gertner, Susan Lee, Gerry Prud'homme, Mike Druckman & Justin Yu on June 13, 2017
Email this postTweet this postLike this postShare this post on LinkedIn

On June 7, 2017, FDA issued a revised guidance document, Form FDA 3674 – Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions, to clarify when sponsors  should submit Form FDA 3674 certifications stating that they have complied with their obligations to submit required clinical trial information to clinicaltrials.gov.  

The requirement for such a certification is contained in the Public Health Service Act, as amended by FDAAA in 2007.  The statute is intended to provide a mechanism for the public to learn about certain clinical trials that are being conducted, as well as summary results information of those trials.  Under the statute, certain types of FDA applications must include a certification stating that the sponsor has met all applicable requirements of the clinicaltrials.gov requirements, namely the requirement to register applicable clinical trials. However, the statutory language does not explain what types of “application or submission” should be accompanied by a certification of compliance.

While it was well understood that certifications would be required for clinical trials included in certain product applications (e.g., NDA, BLA, PMA), FDA has now made it clear that they will also require certifications for INDs and other applications.   In order to address any uncertainty about when such certifications are needed, the recent guidance lists the following types of applications and submissions (including resubmissions) where a certification should be included:

  • IND
  • New Clinical Protocol submitted to an IND
  • NDA
  • Efficacy Supplement to an approved NDA
  • BLA
  • Efficacy Supplement to an approved BLA
  • ANDA
  • PMA
  • PMA Panel Track Supplement
  • HDE
  • 510(k) that refers to, relates to, or includes information on a clinical trial

However, the guidance also states that FDA intends to exercise enforcement discretion with regard to submission of certifications with the following four categories of applications and submissions:

  • Supplements to an approved NDA, BLA, or PMA other than an efficacy supplement (for NDAs and BLAs) or a panel track supplement (for PMAs)
  • Supplements to an approved ANDA
  • INDs for expanded access under 21 USC 360bbb
  • Submission of 510(k)s which do not refer to, relate to, or include information on or from a clinical trial

FDA’s reasoning here is that in contrast to the types of applications and submissions requiring certification, the majority of supplements to approved NDAs, BLAs, and PMAs do not refer to, relate to, or include information on or from a clinical trial.  Because FDA believes that the statutory purposes would not be furthered by the submission of certifications with these four categories, the agency intends to exercise enforcement discretion regarding certification with these applications and submissions.

If you have any questions about the new guidance or the clinicaltrials.gov requirements more generally, please contact one of the authors of this post or the Hogan Lovells attorney with whom you regularly work.

Susan Lee

Susan Lee’s practice focuses on the U.S. Food and Drug Administration’s regulation of pharmaceuticals and biological products. Susan counsels clients on a broad range of FDA legal and regulatory matters, with particular areas of expertise and interest in advertising and promotion issues; the…

Susan Lee’s practice focuses on the U.S. Food and Drug Administration’s regulation of pharmaceuticals and biological products. Susan counsels clients on a broad range of FDA legal and regulatory matters, with particular areas of expertise and interest in advertising and promotion issues; the design and conduct of clinical trials; approval standards for new products; and the FDA-related considerations that arise in the context of acquisitions, collaborations, licensing arrangements, and other types of transactions in the pharmaceutical and biotechnology sector.

Read more about Susan LeeEmail
Show more Show less
  • Posted in:
    Administrative
  • Blog:
    Focus on Regulation
  • Organization:
    Hogan Lovells
  • Article: View Original Source

LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center

New to the Network

  • Boston ERISA & Insurance Litigation Blog
  • Stridon News and Insights
  • Taft Class Action & Consumer Insights
  • Labor and Employment Law Insights
  • Age of Disruption
Copyright © 2022, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo